Log in

NYSE:ZOM - Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Stock Price, Forecast & News

$0.12
-0.01 (-7.48 %)
(As of 02/18/2020 04:28 AM ET)
Add
Today's Range
$0.12
Now: $0.12
$0.13
50-Day Range
$0.12
MA: $0.25
$0.33
52-Week Range
$0.12
Now: $0.12
$1.23
Volume11.44 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.


Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."

How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s Earnings History.

When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

What is the consensus analysts' recommendation for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?

News articles about ZOM stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) investors own include Agile Therapeutics (AGRX), Vaxart (VXRT), Protalix Biotherapeutics (PLX), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), OpGen (OPGN), vTv Therapeutics (VTVT), AcelRx Pharmaceuticals (ACRX), Acasti Pharma (ACST) and Aduro BioTech (ADRO).

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the folowing people:
  • Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
  • Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
  • Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
  • Mr. Bruk Herbst, Chief Commercial Officer (Age 49)

How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?

One share of ZOM stock can currently be purchased for approximately $0.12.


MarketBeat Community Rating for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE ZOM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel